-
2023-508096-36-00
5
2024-10-30
atopic dermatitis
-
2024-516149-38-00
4
2024-10-29
Hodgkin Lymphoma
-
2023-508636-61-00
5
2024-10-24
Crohn’s Disease
-
2024-510584-37-00
4
2024-10-22
Systemic Lupus Erythematosus
-
2024-515870-28-00
5
2024-10-22
Moderate to severe systemic lupus erythematosus
-
2023-509600-15-00
5
2024-10-18
Type 2 Diabetes
-
2024-511796-15-00
5
2024-10-16
Acetylcholine Receptor Binding Antibody Seronegative Generalized Myast
-
2024-511213-38-00
4
2024-10-15
Coeliac disease
-
2024-512676-36-00
10
2024-10-09
Langerhans Cell Histiocytosis
-
2023-504753-12-00
5
2024-10-01
Lung Cancer, Non-Small Cell
-
2024-511705-31-00
5
2024-09-26
Arterial Hypertension
-
2023-503692-24-00
5
2024-09-25
Cutaneous Lupus Erythematosus
-
2023-507851-31-00
5
2024-09-23
Immunoglobulin A Nephropathy (IgAN)
-
2024-511195-33-00
3
2024-09-23
Gastrointestinal tract, biliary tract, or pancreatic cancers with homo
-
2023-506769-67-00
4
2024-09-04
Moderate to Severely Active Ulcerative Colitis
-
2023-509190-23-00
5
2024-09-03
Atherosclerotic Cardiovascular Disease
Elevated lp(a)
-
2024-510965-41-00
5
2024-09-03
Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
-
2024-510908-37-00
5
2024-08-28
KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (
-
2023-504331-41-00
5
2024-08-02
Respiratory tract diseases - Wheezing, Asthma
-
2023-506876-28-00
5
2024-08-01
The medical condition we are investigating is type 1 AMI (STEMI and NS
-
2023-510178-15-00
5
2024-07-31
High-risk Large B-cell Lymphoma
-
2024-512747-23-00
5
2024-07-30
Transfusion-Dependent Alpha- or Beta-Thalassemia
-
2023-507204-31-00
5
2024-07-26
Hidradenitis Suppurativa
-
2023-503923-24-00
5
2024-07-22
Sjögren’s Syndrome With Moderate-toSevere Symptom State